Probenecid sodium

Name: Probenecid sodium
Brand: MedChemExpress
SKU: HY-W404916
Rating: 5.0 (43 reviews)

Cat. No.: HY-W404916 Purity: 99.37%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Probenecid sodium is an orally active, blood-brain barrier-permeable Pannexin 1 channel inhibitor. Probenecid sodium exhibits anti-inflammatory, antiviral, and neuroprotective activities. Probenecid sodium can be used in research related to multiple sclerosis, focal cerebral ischemic injury, influenza virus infection, and nephropathy.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Probenecid sodium 화학구조

CAS No. : 23795-03-1

사이즈	재고	수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
500 mg	해외재고보유	Estimated Time of Arrival: December 31
1 g	해외재고보유	Estimated Time of Arrival: December 31
5 g	해외재고보유	Estimated Time of Arrival: December 31
10 g	해외재고보유	Estimated Time of Arrival: December 31
25 g	해외재고보유	Estimated Time of Arrival: December 31
50 g	해외재고보유	Estimated Time of Arrival: December 31
100 g	해외재고보유	Estimated Time of Arrival: December 31
> 100 g	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 43 publication(s) in Google Scholar

Other Forms of Probenecid sodium:

Probenecid-d₁₄ In-stock
Probenecid In-stock
Probenecid-d₇ 견적 받기

43 Publications Citing Use of MCE Probenecid sodium

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target

TRPV2

In Vitro

Probenecid (0.001-100000 μM; 1-24 h) sodium potently inhibits the replication of Anhui/1-H7N9 in NHBE/A549 cells^[1].
Probenecid (0.001-100000 μM; 1-24 h) sodium potently inhibits the replication of VN/1203-H5N1 in VeroE6 cells, with an IC₅₀ of 0.00003 μM under the condition of 24 h prophylactic treatment and an IC₅₀ of 0.001 μM under the condition of treatment at 1 hour post-infection^[1].
Probenecid sodium inhibits the entry of aristolochic acid into proximal tubular cell lines via human organic anion transporters (OATs) and preserves cell viability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Probenecid (10-100 mg/kg; oral gavage; twice daily for 3 consecutive days) sodium reduces H5N1 influenza-induced body weight loss, decreases pulmonary viral titers, and lowers pro-inflammatory cytokine levels^[1].
Probenecid (150 mg/kg; i.p.; twice daily; up to 8 days) sodium exerts renoprotective effects in a mouse model of aristolochic acid nephropathy, prevents acute kidney injury, alleviates tubulointerstitial injury and DNA repair/proliferation responses, and reduces the levels of advanced aristolochic acid-DNA adducts^[2].
Probenecid (250 mg/kg, i.p., once daily for 20 consecutive days) sodium inhibits symptom progression in mice with autoimmune encephalomyelitis^[3].
Probenecid (1 mg/kg; intraperitoneal injection; twice) sodium significantly reduces cerebral infarction volume and improves neurological function in a mouse model of focal cerebral ischemia^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice (female, 6-8 weeks old)^[1]
Dosage:	10 mg/kg; 100 mg/kg
Administration:	i.g.; twice daily; 3 days
Result:	Maintained stable weight from day 3 pi through day 6 pi. Reduced lung virus titers (10 mg/kg). Eliminated detectable lung virus(100 mg/kg). Caused a significant reduction in serum IL-6, TNF-α, and IL-1β levels on days 3 and 5 pi compared to untreated infected controls (10 mg/kg and 100 mg/kg).

Animal Model:	C57BL/6 mice (12-week-old, experimental autoimmune encephalomyelitis model)^[3]
Dosage:	250 mg/kg
Administration:	i.p.; once daily; 20 days
Result:	Stabilized clinical scores on day 16 post-immunization and maintained unchanged scores for the duration of the experiment, with a significantly lower mean clinical score at day 28 compared to control groups. Achieved 89% survival rate (8 out of 9 mice) by day 35 post-immunization, compared to 50% in untreated EAE mice and less than 65% in solvent-treated mice. Reduced CD3-positive T cell numbers in spinal cords compared to control groups. Decreased CD68-positive activated microglia area in spinal cords compared to control groups. Increased Olig-2-positive oligodendrocyte numbers significantly in spinal cords compared to control groups. Elevated myelinated area (via PAS staining) significantly in spinal cords compared to control groups.

Animal Model:	C57BL/6J mice (male, 25-30 g, focal cerebral ischemia induced by middle cerebral artery occlusion for 60 minutes followed by reperfusion)^[4]
Dosage:	1 mg/kg
Administration:	i.p.; injected immediately before ischemia onset and 2 hours after reperfusion; injected immediately after reperfusion and 3 hours after reperfusion
Result:	Reduced infarct volume and improved neurological score. Attenuated stroke-induced increases in ipsilateral cortical brain water content. Significantly increased the number of NeuN+ neurons in the ischemic core. Significantly reduced the number of CD68+ macrophages/microglia in the ischemic core. Significantly reduced serum HMGB1 concentrations. Downregulated AQP4 protein expression in the cortical penumbra. Reduced activation of GFAP+ astrocytes in the cortical penumbra.

분자량

307.34

화학식

C₁₃H₁₈NNaO₄S

CAS No.

23795-03-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=C(S(=O)(N(CCC)CCC)=O)C=C1)O[Na]

선적

Room temperature in continental US; may vary elsewhere.

보관

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

용액&용해도

In Vitro:

DMSO : ≥ 100 mg/mL (325.37 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2537 mL	16.2686 mL	32.5373 mL
5 mM	0.6507 mL	3.2537 mL	6.5075 mL
10 mM	0.3254 mL	1.6269 mL	3.2537 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

순도&문서

Purity: 99.37%

Select Batch:

Data Sheet (284 KB) SDS (396 KB)

COA (254 KB) HNMR (236 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Murray J, et al. Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses. 2024;16(1):152. Published 2024 Jan 19.

[2]. Baudoux TE, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int. 2012;82(10):1105-1113.

[3]. Hainz N, et al. Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis. Sci Rep. 2017;7(1):17214. Published 2017 Dec 8.

[4]. Xiong XX, et al. Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice. Neurochem Res. 2014;39(1):216-224.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2537 mL	16.2686 mL	32.5373 mL	81.3431 mL
	5 mM	0.6507 mL	3.2537 mL	6.5075 mL	16.2686 mL
	10 mM	0.3254 mL	1.6269 mL	3.2537 mL	8.1343 mL
	15 mM	0.2169 mL	1.0846 mL	2.1692 mL	5.4229 mL
	20 mM	0.1627 mL	0.8134 mL	1.6269 mL	4.0672 mL
	25 mM	0.1301 mL	0.6507 mL	1.3015 mL	3.2537 mL
	30 mM	0.1085 mL	0.5423 mL	1.0846 mL	2.7114 mL
	40 mM	0.0813 mL	0.4067 mL	0.8134 mL	2.0336 mL
	50 mM	0.0651 mL	0.3254 mL	0.6507 mL	1.6269 mL
	60 mM	0.0542 mL	0.2711 mL	0.5423 mL	1.3557 mL
	80 mM	0.0407 mL	0.2034 mL	0.4067 mL	1.0168 mL
	100 mM	0.0325 mL	0.1627 mL	0.3254 mL	0.8134 mL